Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sam who wrote (5860)	1/9/1999 6:49:00 PM
From: Izzy	Read Replies (1) of 6136

Two biotech MSDW analysts follow AGPH: Douglas Lind, M.D. and Christopher Leonard. Altho' neither one would talk to me personally by phone, I do have a written report from them that indicates an excellent knowledge of HIV/AIDS, particularly the various available treatment regimens, including those in clinical trials, particularly Remune, which they interpret as "invoking dramatic immune responses against HIV...To sum it up, we continue to believe Viracept will live up to expectations and that Remune has good potential to become an important new treatment for HIV...we believe Agouron's long-term outlook extends beyond VIRACEPT into the fields of cancer and infectious diseases." They anticipate Remune FDA regulatory filing in 2H99.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next